ABT Aug 2023 105.000 put
| Previous close | 3.7000 |
| Open | 4.2500 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 105.00 |
| Expiry date | 2023-08-18 |
| Day's range | 3.7000 - 4.2700 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Motley Fool2 Dividend Kings Down 12% and 14% You'll Regret Not Buying on The Dip
Dividend Kings are among the most steady corporations on the market. While many businesses don't even last a decade, these companies have survived and thrived and raised their payouts for at least 50 consecutive years to become a member of this elite group. Case in point: Abbott Laboratories (NYSE: ABT) and Johnson & Johnson (NYSE: JNJ) are two members of this prominent clique that have lagged the market recently, partly due to company-specific concerns.
ZacksAbbott (ABT) Gains But Lags Market: What You Should Know
In the latest trading session, Abbott (ABT) closed at $102.82, marking a +0.8% move from the previous day.
ZacksAbbott (ABT) Gains As Market Dips: What You Should Know
Abbott (ABT) closed at $102 in the latest trading session, marking a +0.29% move from the prior day.
ZacksAbbott (ABT) Reports Upbeat Cardiomems Sensor Study Result
Abbott's (ABT) MONITOR-HF is the third randomized, controlled trial that will provide significant health benefits to indicated heart failure patients.
ZacksAbbott (ABT) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Abbott (ABT) closed at $102.14, marking a -1.83% move from the previous day.
- Zacks
Abbott (ABT) Unveils Late-Breaking Data on Leadless Pacemaker
Abbott (ABT) study analyzes primary safety and efficacy endpoints in the first 300 people enrolled across 55 centers in the United States, Canada and Europe.
- Financial Times
Infant formula producers probed by FTC over bids for government contracts
Inquiry by US regulator focuses on whether manufacturers colluded in relation to programme for low-income families
Yahoo Finance VideoFTC investigating baby-formula makers on suspected collusion
Yahoo Finance health care reporter Anjalee Khemlani discusses the ongoing investigation by the FTC of baby-formula makers, including Abbott Laboratories, Perrigo, and Nestle, on suspected collusion.
ReutersAbbott, baby formula makers face FTC probe for potential collusion
The FTC is looking into whether the companies "engaged in collusion or coordination with any other market participant regarding the bidding," according to the document. The Wall Street Journal was first to report the probe. According to the document, in 2022 the FTC began looking into potential collusion or coordination in bids to provide formula for the U.S. Department of Agriculture's Women, Infants and Children (WIC) program that provides free formula to low-income families.
ZacksAbbott (ABT) Expands in Electrophysiology With New FDA Nod
Abbott (ABT) notes that using TactiFlex catheter can lead to reduced procedure times and better safety compared to the company's previous generation catheters.
- Zacks
Abbott's (ABT) Assert-IQ Cardiac Monitor Receives FDA Approval
Abbott's (ABT) latest approval adds to its line-up of remote patient management and treatment tools that can support doctors more effectively.
ZacksAbbott (ABT) Down 1.7% Since Last Earnings Report: Can It Rebound?
Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ReutersAbbott Labs is sued over PediaSure height claims
NEW YORK (Reuters) -A New York City woman sued Abbott Laboratories on Monday, accusing the healthcare company of misleading consumers into believing its PediaSure nutrition drinks were "clinically proven" to increase children's height. In a proposed class action filed in Manhattan federal court, Joanne Noriega said she bought PediaSure Grow & Gain vanilla and strawberry drinks for her eight-year-old grandson, who was "short for his age," believing they would help him get taller. The Bronx resident said that by February, after a year of two PediaSure drinks per day, her grandson was still short for his age and had become "so overweight" that she stopped buying the drinks.
- Zacks
Abbott's (ABT) New Pact to Advance Clinical Trials Diversity
Abbott's (ABT) latest additions to Diversity in Clinical Trials effort expand upon the alliances, awards and the emphasis on diverse participation in its own clinical trials.
- Zacks
Here's Why You Should Retain Abbott (ABT) Stock For Now
Investors are optimistic about Abbott (ABT) on continued growth in the core Diagnostics arm.
- Zacks
Abbott (ABT) EPD Business Grows Strong, Macro Issues Stay
Abbott (ABT) continues to make good progress, increasing manufacturing production and recovering market share in the Nutrition business.
ZacksCigna (CI) Q1 Earnings Surpass Estimates, Ups '23 EPS View
Cigna's (CI) first-quarter 2023 results indicate a strong contribution to revenues from Evernorth Health Services and Cigna Healthcare businesses. Management currently expects adjusted EPS to be a minimum of $24.70 in 2023.
ZacksThe Zacks Analyst Blog Highlights Berkshire Hathaway, Tesla, JPMorgan Chase, Abbott Laboratories and Comcast
Berkshire Hathaway, Tesla, JPMorgan Chase, Abbott Laboratories and Comcast are included in this Analyst Blog.
ZacksAcadia Healthcare (ACHC) Q1 Earnings Beat on Higher Patient Volumes
Acadia Healthcare's (ACHC) Q1 results reflect higher revenue per patient day, partly offset by an elevated cost level. Management reaffirms its 2023 business guidance.
Motley FoolIs Dexcom a Good Stock to Buy Now?
A poorly received first-quarter earnings report has investors wondering if this stock's best days are behind it.
Motley FoolGot $1,000? 2 Top Dividend Stocks to Buy Now
If you're looking to grow your $1,000, you can do that by investing in stocks that probably will deliver share performance. Let's check out two top Dividend Kings to buy now. You may know of Abbott because of its enormous COVID-19 testing business.
Motley FoolWhy Abbott Laboratories Stock Looks Ridiculously Overpriced
Abbott Laboratories (NYSE: ABT) has had a volatile couple of years. It benefited from COVID-related tests boosting its sales, but last year it ran into manufacturing issues that affected its baby formula production and hurt sales in its nutritional segment. The business is now getting back to normal, but the problem is that its valuation still needs to come down significantly before it's a worthwhile buy.
ZacksCentene (CNC) Q1 Earnings Miss Estimates, '23 EPS View Raised
Centene's (CNC) first-quarter 2023 results grapple with higher operating expenses, partly offset by an expanding customer base. Management presently expects adjusted EPS to be at least $6.40 in 2023.
Motley FoolSleep Easy With These 2 Rock-Solid Dividend Stocks
There's nothing quite as nasty a surprise as seeing one of your investments slash its dividend. Abbott Laboratories (NYSE: ABT) is among the most solid dividend stocks out there. As one of the largest healthcare businesses in the world, with a vast and heavily diversified base of revenue, it isn't too hard to appreciate why it could make for a decent and fairly safe investment.
Motley FoolIs Abbott Laboratories Stock a Buy for Dividend Investors?
Dividend growth investing is among the most common investing strategies around, and for good reason: Buying quality businesses and dividend growth stocks often go hand in hand. With at least 50 consecutive years of payout growth, Dividend Kings are the most reliable dividend growers in the investment universe. Abbott Laboratories (NYSE: ABT) has delivered 51 consecutive years of dividend growth to its shareholders.